<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913832</url>
  </required_header>
  <id_info>
    <org_study_id>180013</org_study_id>
    <nct_id>NCT03913832</nct_id>
  </id_info>
  <brief_title>TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon</brief_title>
  <acronym>TRANSFORM I</acronym>
  <official_title>Magic Touch Sirolimus Coated Balloon (Concept Medical) Versus SeQuent Pease Neo Paclitaxel Coated Balloon (Bbraun) for the Treatment of de Novo Coronary Artery Lesions in Small Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concept Medicals BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concept Medicals BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multinational (Italy and UK), multicenter, randomised Clinical&#xD;
      Trial that compares the efficacy and performance of two drug coated balloon (DCB), the MAGIC&#xD;
      TOUCH sirolimus coated balloon (Concept Medical) and SeQuent Please paclitaxel coated balloon&#xD;
      (B Braun). The objective of the study is to compare angiographic outcomes of Magic TouchTM&#xD;
      sirolimus coated balloon (Concept Medical) versus SeQuentTM paclitaxel coated balloon&#xD;
      (Bbraun) for the treatment of de novo coronary artery lesions in small vessels (≤2.5 mm) with&#xD;
      respect to Net Gain (mm) at 6 months follow-up&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, multi-centre study in subjects with small vessels, i.e. at least&#xD;
      one de-novo lesion in a small vessel (≤2.5mm). Vessel size will be determined first by QCA&#xD;
      on-line (screening, pre-procedure). If, based on QCA on-line the vessel size pre-procedure is&#xD;
      ≤2.5mm and following a successful pre-dilatation (i.e. no angiographic dissections type CDEF&#xD;
      and TIMI&gt;2), the subject will be randomized in a 1:1 fashion to Magic Touch or SeQuent Please&#xD;
      Neo. OCT will be performed post pre-dilatation (guidance) prior to drug coated balloon (DCB)&#xD;
      treatment. The DCB balloon size will be selected based on OCT measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Gain (mm) In-segment</measure>
    <time_frame>6 Months</time_frame>
    <description>The primary endpoint is in-segment (balloon treated area) Net Gain (mm) at 6 months post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Post procedure (Right after the treatment with drug coated balloon)</time_frame>
    <description>Successful delivery and inflation within 45 seconds of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use) and successful withdrawal of the device system with attainment of final in-lesion residual stenosis of &lt;30% (by Quantitative Coronary angiography).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>Post procedure (Right after the treatment with drug coated balloon)</time_frame>
    <description>Successful delivery and inflation within 45 seconds of the allocated DCB device at all intended target lesion(s) during an attempt with a DCB not previously used (first use) and successful withdrawal of the device system with attainment of final in-lesion residual stenosis of &lt;30% (by QCA) without the occurrence of TLF during the index procedure hospital stay).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute/subacute/early/late vessel closure/thrombosis</measure>
    <time_frame>1, 6 months and 12 Months</time_frame>
    <description>Closure by restenosis or thrombosis (diameter stenosis of 100% and/or TIMI grade 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic outcomes: late lumen loss</measure>
    <time_frame>6 months</time_frame>
    <description>The difference between the minimum lumen diameter (MLD) immediately after index procedure and the MLD at follow-up as measured in (preferable) identical orthogonal views (MLDpost - MLDfup).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic outcomes:Minimal lumen diameter</measure>
    <time_frame>6 months</time_frame>
    <description>The smallest lumen diameter in the segment of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic outcomes: Percent diameter stenosis</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of luminal narrowing of vessel segment of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic outcomes: Restenosis rate</measure>
    <time_frame>6 months</time_frame>
    <description>Restenosis is defined as ≥50% diameter stenosis at follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device oriented Composite Endpoint (DoCE / TLF): Cardiac death</measure>
    <time_frame>1, 6 months and 12 Months</time_frame>
    <description>Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device oriented Composite Endpoint (DoCE / TLF): Target vessel: myocardial infarction (TV-MI)</measure>
    <time_frame>1, 6 months and 12 Months</time_frame>
    <description>The term myocardial injury should be used when there is evidence of elevated cardiac troponin values (cTn) with at least one value above the 99th percentile upper reference limit (URL) TV-MI: Myocardial Infarction not clearly attributable to a non-target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device oriented Composite Endpoint (DoCE / TLF): clinically indicated target lesion revascularization(TLR)</measure>
    <time_frame>1, 6 months and 12 Months</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>DCB</condition>
  <arm_group>
    <arm_group_label>sirolimus drug coated balloon (SCB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel releasing coronary balloon catheter.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus drug coated balloon (SCB)</intervention_name>
    <description>Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology &quot;Nanolute&quot;. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions &amp; de novo lesions.</description>
    <arm_group_label>sirolimus drug coated balloon (SCB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel releasing coronary balloon catheter</intervention_name>
    <description>SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.</description>
    <arm_group_label>paclitaxel releasing coronary balloon catheter.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥18 years&#xD;
&#xD;
          2. Patient with chronic stable angina or stabilized acute coronary syndromes with normal&#xD;
             cardiac biomarker values&#xD;
&#xD;
             Note: For patients showing elevated Troponin (e.g. non-STEMI patients) at baseline&#xD;
             (within 72h pre-PCI) an additional blood sample must be collected prior to&#xD;
             randomization to confirm that:&#xD;
&#xD;
               -  hs-cTn or Troponin I or T levels are stable, i.e. the value should be within 20%&#xD;
                  range of the value found in the first sample at baseline, or have dropped&#xD;
&#xD;
               -  CK-MB and CK levels are within normal range If hs-cTn or Troponin I or T levels&#xD;
                  are stable or have dropped, the CK-MB and CK levels are within normal ranges, and&#xD;
                  the ECG is normal, the patient may be included in the study.&#xD;
&#xD;
          3. The patient has a planned intervention in one or two separate major epicardial&#xD;
             territories (LAD, LCX or RCA) and has at least one de-novo lesion in a small vessel&#xD;
             (≤2.5mm by QCA prior to pre-dilatation)&#xD;
&#xD;
          4. Target lesion reference diameter ≤2.50 mm as assessed by OCT (post pre-dilatation)&#xD;
&#xD;
          5. Target lesion length ≤30 mm&#xD;
&#xD;
          6. Able to understand and provide informed consent and comply with all study procedures&#xD;
             including 6 months angiographic follow-up&#xD;
&#xD;
          7. Patient must have completed the follow-up phase of any previous study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed&#xD;
             within 7 days prior to the index procedure in women of child-bearing potential)&#xD;
&#xD;
          2. Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac&#xD;
             biomarkers (according to local standard hospital practice) have not returned within&#xD;
             normal limits at the time of procedure&#xD;
&#xD;
          3. Known contraindication or hypersensitivity to sirolimus, paclitaxel, or to medications&#xD;
             such as aspirin, heparin, and all of the following four medications: clopidogrel&#xD;
             bisulfate, ticlopidine, prasugrel, ticagrelor&#xD;
&#xD;
          4. Patient suffered from stroke/TIA during the last 6 months&#xD;
&#xD;
          5. LVEF &lt;30%&#xD;
&#xD;
          6. Platelet count &lt;100,000 cells/mm3 or &gt;400,000 cells/mm3, a WBC of &lt;3,000 cells/mm3, or&#xD;
             documented or suspected liver disease (including laboratory evidence of hepatitis)&#xD;
&#xD;
          7. Known renal insufficiency (e.g. serum creatinine &gt;2.5mg/dL, or creatinine clearance&#xD;
             ≤30 mL/min), or subject on dialysis, or acute kidney failure (as per physician&#xD;
             judgment)&#xD;
&#xD;
          8. Patient undergoing planned surgery within 6 months with the necessity to stop DAPT&#xD;
&#xD;
          9. History of bleeding diathesis or coagulopathy&#xD;
&#xD;
         10. The patient is a recipient of a heart transplant&#xD;
&#xD;
         11. Concurrent medical condition with a life expectancy of less than 12 months&#xD;
&#xD;
         12. The patient is unwilling/not able to return for angiographic recatherisation at 6&#xD;
             month follow-up&#xD;
&#xD;
         13. Currently participating in another trial and not yet at its primary endpoint.&#xD;
&#xD;
             Angiographic exclusion criteria:&#xD;
&#xD;
         14. The patient has a planned intervention in three separate major epicardial territories&#xD;
             (3 vessel disease)&#xD;
&#xD;
         15. The patient has a planned intervention in the left-main plus two separate major&#xD;
             epicardial territories (left-main plus 2 vessel disease)&#xD;
&#xD;
         16. Target vessel size &gt;2.50 mm&#xD;
&#xD;
         17. Target lesion has a total occlusion or TIMI flow &lt;2&#xD;
&#xD;
         18. Target lesion in left main stem&#xD;
&#xD;
         19. The target vessel contains visible thrombus&#xD;
&#xD;
         20. Target Restenotic lesion&#xD;
&#xD;
         21. Aorto-ostial target lesion (within 3 mm of the aorta junction)&#xD;
&#xD;
         22. Moderate-severe tortuous, calcified or angulated coronary anatomy of the target vessel&#xD;
             that in the opinion of the investigator would result in suboptimal imaging or&#xD;
             excessive risk of complication from placement of an OCT catheter&#xD;
&#xD;
         23. Lesion is located within an arterial or saphenous vein graft or distal to a diseased&#xD;
             arterial or saphenous vein graft.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Serruys, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>NUIG Imaging CoreLab</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernardo Cortese, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica San Carlo - Paderno Dugnano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dario Gattuso</last_name>
    <phone>+39 329 246 7132</phone>
    <email>dario@conceptmedicals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maria Cecilia Hospital spa</name>
      <address>
        <city>Cotignola</city>
        <state>Emilia-Romagna</state>
        <zip>48033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Colombo, Dr.</last_name>
      <phone>39 0545 217111</phone>
      <email>ac84344@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Letizia Lunetto</last_name>
      <email>llunetto@gvmnet.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Colombo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Giannini, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Mangieri, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Lombardy</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Testa, Dr.</last_name>
      <phone>39 02 527741</phone>
      <email>luctes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luca Testa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOUC Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo di Mario, Dr</last_name>
      <phone>(+ 39) 055 794 111</phone>
      <email>carlo.dimario@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Carlo di Mario, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierluigi Demola, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessio Mattesini, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Trust, Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandeep Basavarajaiah, Dr</last_name>
      <phone>44 121 424 2000</phone>
      <email>sandeep270478@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Basavarajaiah, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helen Routledge, Dr</last_name>
      <phone>44 1905 763333</phone>
      <email>h.routledge@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Helen Routledge, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small vessel</keyword>
  <keyword>sirolimus</keyword>
  <keyword>drug coating balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

